Prognostic and Predictive Models in Myelofibrosis.

IF 2.7 3区医学 Q2 HEMATOLOGY Current Hematologic Malignancy Reports Pub Date : 2024-10-01 Epub Date: 2024-08-24 DOI:10.1007/s11899-024-00739-6

Barbara Mora, Cristina Bucelli, Daniele Cattaneo, Valentina Bellani, Francesco Versino, Kordelia Barbullushi, Nicola Fracchiolla, Alessandra Iurlo, Francesco Passamonti

{"title":"Prognostic and Predictive Models in Myelofibrosis.","authors":"Barbara Mora, Cristina Bucelli, Daniele Cattaneo, Valentina Bellani, Francesco Versino, Kordelia Barbullushi, Nicola Fracchiolla, Alessandra Iurlo, Francesco Passamonti","doi":"10.1007/s11899-024-00739-6","DOIUrl":null,"url":null,"abstract":"Purpose of review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.Recent findings: Discoveries on the impact of the biological architecture on OS have led to the design of integrated scores to predict survival in PMF. For SMF, OS estimates should be calculated by the specific MYSEC-PM (MYelofibrosis SECondary-prognostic model). Information on the prognostic role of the molecular landscape in SMF is accumulating. Crucial treatment decisions for MF patients could be now supported by multivariable predictive algorithms. OS should become a relevant endpoint of clinical trials. Prognostic models guide prediction of OS and treatment planning in MF, therefore, their timely application is critical in the personalized approach of MF patients.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":" ","pages":"223-235"},"PeriodicalIF":2.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416430/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-024-00739-6","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/24 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven and nine years, respectively. Main causes of mortality are non-clonal progression and transformation into blast phase.

Recent findings: Discoveries on the impact of the biological architecture on OS have led to the design of integrated scores to predict survival in PMF. For SMF, OS estimates should be calculated by the specific MYSEC-PM (MYelofibrosis SECondary-prognostic model). Information on the prognostic role of the molecular landscape in SMF is accumulating. Crucial treatment decisions for MF patients could be now supported by multivariable predictive algorithms. OS should become a relevant endpoint of clinical trials. Prognostic models guide prediction of OS and treatment planning in MF, therefore, their timely application is critical in the personalized approach of MF patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨髓纤维化的预后和预测模型

审查目的：骨髓纤维化（MF）包括纤维化前原发性骨髓纤维化（pre-PMF）、过度骨髓纤维化（over-PMF）和继发性骨髓纤维化（SMF）。前骨髓纤维化原发性骨髓纤维化、过度骨髓纤维化原发性骨髓纤维化和继发性骨髓纤维化原发性骨髓纤维化患者的中位总生存期（OS）分别约为14年、7年和9年。死亡的主要原因是非克隆性进展和转化为爆破期：最近的研究结果：生物结构对OS影响的发现促使人们设计出预测PMF生存率的综合评分。对于SMF，OS估计值应通过特定的MYSEC-PM（骨髓纤维化二级预后模型）来计算。有关 SMF 分子图谱预后作用的信息正在不断积累。现在，多变量预测算法可为骨髓纤维化患者的关键治疗决策提供支持。OS应成为临床试验的相关终点。预后模型可指导MF的OS预测和治疗计划，因此，及时应用预后模型对于MF患者的个性化治疗至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.